{"id":"https://openalex.org/W2146286204","doi":"https://doi.org/10.1111/j.1463-1326.2008.00883.x","title":"Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France","display_name":"Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France","alternate_titles":[],"publication_year":2008,"publication_date":"2008-04-23","ids":{"openalex":"https://openalex.org/W2146286204","doi":"https://doi.org/10.1111/j.1463-1326.2008.00883.x","mag":"2146286204","pmid":"https://pubmed.ncbi.nlm.nih.gov/18435670"},"language":"en","primary_location":{"id":"doi:10.1111/j.1463-1326.2008.00883.x","doi":"https://doi.org/10.1111/j.1463-1326.2008.00883.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2008.00883.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2146286204"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112061389","display_name":"Patrick Vexiau","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]},{"id":"https://openalex.org/I4210144610","display_name":"H\u00f4pital Saint-Louis","ror":"https://ror.org/049am9t04","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210144610"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"P. Vexiau","raw_affiliation_strings":["Department of Diabetology and Endocrinology, H\u00f4pital Saint-Louis, Assistance publique-H\u00f4pitaux de Paris, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Diabetology and Endocrinology, H\u00f4pital Saint-Louis, Assistance publique-H\u00f4pitaux de Paris, Paris, France","institution_ids":["https://openalex.org/I4210097159","https://openalex.org/I4210144610"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042314963","display_name":"Panagiotis Mavros","orcid":"https://orcid.org/0000-0002-6647-102X","observed_orcids":["https://orcid.org/0000-0002-6647-102X"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"P. Mavros","raw_affiliation_strings":["Global Health Outcomes Research & Health Technology Assessment, Merck & Co., Inc., Whitehouse Station, NJ, USA","Global Health Outcomes Research and Health Technology Assessment, Merck & Co., Inc., Whitehouse Station, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Health Outcomes Research & Health Technology Assessment, Merck & Co., Inc., Whitehouse Station, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"Global Health Outcomes Research and Health Technology Assessment, Merck & Co., Inc., Whitehouse Station, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034135253","display_name":"Girishanthy Krishnarajah","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"G. Krishnarajah","raw_affiliation_strings":["Former Merck & Co. employee","Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Former Merck & Co. employee","institution_ids":[]},{"raw_affiliation_string":"Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071232796","display_name":"R. Lyu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"R. Lyu","raw_affiliation_strings":["Global Health Outcomes Research & Health Technology Assessment, Merck & Co., Inc., Whitehouse Station, NJ, USA","Global Health Outcomes Research and Health Technology Assessment, Merck & Co., Inc., Whitehouse Station, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Health Outcomes Research & Health Technology Assessment, Merck & Co., Inc., Whitehouse Station, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"Global Health Outcomes Research and Health Technology Assessment, Merck & Co., Inc., Whitehouse Station, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111804848","display_name":"D. Yin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"D. Yin","raw_affiliation_strings":["Global Health Outcomes Research & Health Technology Assessment, Merck & Co., Inc., Whitehouse Station, NJ, USA","Global Health Outcomes Research and Health Technology Assessment, Merck & Co., Inc., Whitehouse Station, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Health Outcomes Research & Health Technology Assessment, Merck & Co., Inc., Whitehouse Station, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"Global Health Outcomes Research and Health Technology Assessment, Merck & Co., Inc., Whitehouse Station, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5111804848"],"corresponding_institution_ids":["https://openalex.org/I1285764155"],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":null,"fwci":3.958,"has_fulltext":false,"cited_by_count":117,"citation_normalized_percentile":{"value":0.93998768,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":100},"biblio":{"volume":"10","issue":"s1","first_page":"16","last_page":"24"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.5541999936103821,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.5541999936103821,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.41359999775886536,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10793","display_name":"Diabetes Management and Education","score":0.014700000174343586,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.9909999966621399},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9950000047683716},{"id":"https://openalex.org/keywords/metformin","display_name":"metformin","score":0.9959999918937683},{"id":"https://openalex.org/keywords/sulfonylureas","display_name":"sulfonylureas","score":0.9210000038146973},{"id":"https://openalex.org/keywords/combination-antidiabetic-therapy","display_name":"combination antidiabetic therapy","score":0.7889999747276306},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.7960000038146973},{"id":"https://openalex.org/keywords/hypoglycaemic-symptoms","display_name":"hypoglycaemic symptoms","score":0.7839999794960022},{"id":"https://openalex.org/keywords/eq-5d","display_name":"EQ-5D","score":0.9879999756813049},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.7360000014305115},{"id":"https://openalex.org/keywords/primary-care-patients","display_name":"primary care patients","score":0.871999979019165},{"id":"https://openalex.org/keywords/france","display_name":"France","score":0.46700000762939453},{"id":"https://openalex.org/keywords/health-related-quality-of-life","display_name":"health-related quality of life","score":0.7630000114440918}],"concepts":[{"id":"https://openalex.org/C2779978724","wikidata":"https://www.wikidata.org/wiki/Q1436482","display_name":"Worry","level":3,"score":0.8874348402023315},{"id":"https://openalex.org/C2780323712","wikidata":"https://www.wikidata.org/wiki/Q19484","display_name":"Metformin","level":3,"score":0.881338357925415},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8801893591880798},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6261797547340393},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5889232754707336},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.5703149437904358},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5529532432556152},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.5421519875526428},{"id":"https://openalex.org/C2780668416","wikidata":"https://www.wikidata.org/wiki/Q202758","display_name":"Hypoglycemia","level":3,"score":0.4766710102558136},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.43562251329421997},{"id":"https://openalex.org/C142052008","wikidata":"https://www.wikidata.org/wiki/Q954027","display_name":"Cross-sectional study","level":2,"score":0.41001415252685547},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.34580308198928833},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.20092567801475525},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.13131648302078247},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.0639382004737854},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D003430","descriptor_name":"Cross-Sectional Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005602","descriptor_name":"France","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D005905","descriptor_name":"Glyburide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005913","descriptor_name":"Glipizide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007003","descriptor_name":"Hypoglycemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D007003","descriptor_name":"Hypoglycemia","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D007003","descriptor_name":"Hypoglycemia","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008687","descriptor_name":"Metformin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D008687","descriptor_name":"Metformin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013315","descriptor_name":"Stress, Psychological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013453","descriptor_name":"Sulfonylurea Compounds","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013453","descriptor_name":"Sulfonylurea Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1463-1326.2008.00883.x","doi":"https://doi.org/10.1111/j.1463-1326.2008.00883.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2008.00883.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmid:18435670","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18435670","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":27,"referenced_works":["https://openalex.org/W102529081","https://openalex.org/W1886712785","https://openalex.org/W1965510020","https://openalex.org/W1966016127","https://openalex.org/W1969626373","https://openalex.org/W1973560164","https://openalex.org/W1983664900","https://openalex.org/W2008006848","https://openalex.org/W2019943219","https://openalex.org/W2025168202","https://openalex.org/W2028873098","https://openalex.org/W2053144796","https://openalex.org/W2058831278","https://openalex.org/W2062579067","https://openalex.org/W2066696238","https://openalex.org/W2079889285","https://openalex.org/W2080220293","https://openalex.org/W2081228664","https://openalex.org/W2100442612","https://openalex.org/W2101481281","https://openalex.org/W2104113021","https://openalex.org/W2107648636","https://openalex.org/W2124142873","https://openalex.org/W2153836018","https://openalex.org/W2337454357","https://openalex.org/W2340632664","https://openalex.org/W2473786944"],"related_works":["https://openalex.org/W2052404210","https://openalex.org/W2735508711","https://openalex.org/W2114610883","https://openalex.org/W2147007805","https://openalex.org/W2112136918","https://openalex.org/W2158312041","https://openalex.org/W2981493587","https://openalex.org/W2047076943","https://openalex.org/W2199937012","https://openalex.org/W2767092674"],"abstract_inverted_index":{"CONTEXT:":[0],"Hypoglycaemia":[1],"from":[2],"antihyperglycaemic":[3],"drugs":[4],"may":[5],"have":[6],"a":[7,21,121,330],"significant":[8],"impact":[9,29,56],"on":[10,32,59,197,244,259],"patients'":[11,60],"health-related":[12,315],"quality":[13,33,61,316],"of":[14,18,30,34,48,57,62,67,83,98,143,154,169,176,226,236,284,302,317],"life.":[15],"Combination":[16],"use":[17,66],"metformin":[19,119,328],"and":[20,54,113,120,141,160,186,222,300,313,329],"sulphonylurea":[22,68,122],"has":[23],"become":[24],"increasingly":[25],"common;":[26],"yet,":[27],"the":[28,55,147,151,155,161,198,245,260,282,290],"hypoglycaemia":[31,58,209,237,268,285,312],"life":[35,63,318],"in":[36,88,146,279],"these":[37],"patients":[38,100,172,205,253,265,323],"is":[39],"not":[40,215,274],"well":[41],"documented.":[42],"OBJECTIVE:":[43],"To":[44],"examine":[45],"patient-reported":[46],"experience":[47,283],"hypoglycaemia,":[49,175],"worry":[50,310],"about":[51,311],"hypoglycaemic":[52,144,227,255,303],"symptoms":[53,145,235,304],"associated":[64,240,288,306],"with":[65,70,101,118,224,241,254,289,307,326],"co-administered":[69],"metformin.":[71],"DESIGN:":[72],"This":[73],"was":[74,202,286],"an":[75],"observational,":[76],"cross-sectional,":[77],"multi-centre":[78],"study.":[79],"SETTING:":[80],"A":[81,96,167],"total":[82,97,168],"98":[84],"primary":[85,133],"care":[86,134],"centres":[87],"France":[89],"during":[90,130],"October":[91],"to":[92],"December":[93],"2005.":[94],"PATIENTS:":[95],"400":[99],"type":[102,320],"2":[103,321],"diabetes,":[104],"who":[105,114,206,213,266,272],"were":[106,238,262,305],">":[107],"or":[108,191],"=":[109,250,276],"35":[110],"years":[111],"old":[112],"had":[115],"been":[116],"treated":[117,325],"for":[123,204,211,264,270],"at":[124],"least":[125],"6":[126,149],"months,":[127,150],"completed":[128],"questionnaires":[129],"their":[131],"usual":[132],"office":[135],"visit.":[136],"MAIN":[137],"OUTCOME":[138],"MEASURES:":[139],"Frequency":[140],"severity":[142,225,301],"past":[148],"Worry":[152,200,247],"subscale":[153],"Hypoglycaemic":[156],"Fear":[157],"Survey-II":[158],"(HFS-II)":[159],"EuroQol-5":[162],"Dimensions":[163],"(EQ-5D)":[164],"questionnaire.":[165],"RESULTS:":[166],"136":[170],"(34%)":[171],"reported":[173,207,267],"experiencing":[174],"whom":[177],"78":[178],"(58%)":[179],"experienced":[180,184,189],"mild,":[181],"40":[182],"(30%)":[183],"moderate":[185],"16":[187],"(12%)":[188],"severe":[190,193,234],"very":[192],"symptoms.":[194,228,256],"Mean":[195],"score":[196,293],"HFS-II":[199,246],"scale":[201,248],"higher":[203,242],"having":[208],"than":[210,269],"those":[212,271],"did":[214,273],"(19.0":[216],"vs.":[217],"10.2;":[218],"p":[219],"<":[220,295],"0.0001)":[221,277],"increased":[223,308],"In":[229],"linear":[230],"regression":[231],"analyses,":[232],"more":[233],"significantly":[239],"scores":[243,258],"(p":[249,275,294],"0.0162)":[251],"among":[252,319],"Summary":[257],"EQ-5D":[261,291],"lower":[263,314],"and,":[278],"multivariate":[280],"analysis,":[281],"negatively":[287],"summary":[292],"0.0001).":[296],"CONCLUSION:":[297],"The":[298],"occurrence":[299],"patient":[309],"diabetic":[322],"being":[324],"both":[327],"sulphonylurea.":[331]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2146286204","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":8},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":14},{"year":2014,"cited_by_count":17},{"year":2013,"cited_by_count":11},{"year":2012,"cited_by_count":12}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
